Literature DB >> 12751658

A practical approach to hypercalcemia.

Mary F Carroll1, David S Schade.   

Abstract

Hypercalcemia is a disorder commonly encountered by primary care physicians. The diagnosis often is made incidentally in asymptomatic patients. Clinical manifestations affect the neuromuscular, gastrointestinal, renal, skeletal, and cardiovascular systems. The most common causes of hypercalcemia are primary hyperparathyroidism and malignancy. Some other important causes of hypercalcemia are medications and familial hypocalciuric hypercalcemia. An initial diagnostic work-up should include measurement of intact parathyroid hormone, and any medications that are likely to be causative should be discontinued. Parathyroid hormone is suppressed in malignancy-associated hypercalcemia and elevated in primary hyperparathyroidism. It is essential to exclude other causes before considering parathyroid surgery, and patients should be referred for parathyroidectomy only if they meet certain criteria. Many patients with primary hyperparathyroidism have a benign course and do not need surgery. Hypercalcemic crisis is a life-threatening emergency. Aggressive intravenous rehydration is the mainstay of management in severe hypercalcemia, and antiresorptive agents, such as calcitonin and bisphosphonates, frequently can alleviate the clinical manifestations of hypercalcemic disorders.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12751658

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  42 in total

1.  Prevalence and risk factors for hypercalcemia among non-dialysis patients with chronic kidney disease-mineral and bone disorder.

Authors:  Jun Jie Benjamin Seng; Ying Lin Cheryl Tan; Rou Wei Lim; Hui Ting Sarah Ng; Puay Hoon Lee; Jiunn Wong
Journal:  Int Urol Nephrol       Date:  2018-06-07       Impact factor: 2.370

2.  54-year-old woman with fatigue, back pain, and hypercalcemia.

Authors:  D Brian Newman; Jamie J Kearns; Thomas J Beckman
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

3.  Regulatory inhibition of biological tissue mineralization by calcium phosphate through post-nucleation shielding by fetuin-A.

Authors:  Joshua C Chang; Robert M Miura
Journal:  J Chem Phys       Date:  2016-04-21       Impact factor: 3.488

4.  Diagnosing the Treatment.

Authors:  Sarah A McGuffin; Robert L Trowbridge; Ann M O'Hare; Andrew P Olson
Journal:  J Hosp Med       Date:  2018-06-27       Impact factor: 2.960

5.  Immobilization induced hypercalcemia.

Authors:  Edgar Alonso Cano-Torres; Arnulfo González-Cantú; Gabriela Hinojosa-Garza; Fernando Castilleja-Leal
Journal:  Clin Cases Miner Bone Metab       Date:  2016-05-11

Review 6.  [Hypercalcemic crisis and hypocalcemic tetany].

Authors:  C Kasperk
Journal:  Internist (Berl)       Date:  2017-10       Impact factor: 0.743

7.  Detection of Tumor Cell-Induced Platelet Aggregation and Granule Secretion.

Authors:  Svenja Schwarz; Martin Schlesinger; Gerd Bendas
Journal:  Methods Mol Biol       Date:  2021

8.  The effect of monthly 50,000 IU or 100,000 IU vitamin D supplements on vitamin D status in premenopausal Middle Eastern women living in Auckland.

Authors:  H Mazahery; W Stonehouse; P R von Hurst
Journal:  Eur J Clin Nutr       Date:  2014-12-10       Impact factor: 4.016

9.  Prevalence of hypercalcemia in hospitalised patients: effects of "correction" for serum albumin values.

Authors:  V Carnevale; M Pipino; M Antonacci; C Checchia; V D'Alessandro; M Errico; A Greco; A Varriale
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

10.  Risk of hypercalcemia in blacks taking hydrochlorothiazide and vitamin D.

Authors:  Paulette D Chandler; Jamil B Scott; Bettina F Drake; Kimmie Ng; John P Forman; Andrew T Chan; Gary G Bennett; Bruce W Hollis; Edward L Giovannucci; Karen M Emmons; Charles S Fuchs
Journal:  Am J Med       Date:  2014-03-20       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.